TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7450653
Drug: Suppository (Euphyllin)
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository (Euphyllin)
Study: 7450653
Drug: Intravenous preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous preparation
Study: 31658037
Drug: Osteopathic manipulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulation treatment group (OMTG - n=23)
Study: 25053388
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg veliparib (new formulation) under fasting conditions
Study: 25053388
Drug: Four 10
Normalized name: Wal-Four 10 MG/ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 10 mg current formulation capsules under fasting conditions
Study: 25053388
Drug: Four 10
Normalized name: Wal-Four 10 MG/ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 10 mg new formulation under fasting conditions
Study: 20421537
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus carboplatin (paclitaxel at 175 mg/m² IV over 3 hours plus carboplatin AUC = 6 IV over 30 minutes every 3 weeks)
Study: 18826988
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 or 600 mg for 1 day; 300 + 75 or 150 mg daily for 7 days)
Study: 2205135
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam 0.3 mg.kg‐1
Study: 12472704
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.5 mg.kg(‐1)
Study: 12472704
Drug: Rectal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal midazolam 0.5 mg.kg(‐1)
Study: 12472704
Drug: Sublingual midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sublingual midazolam 0.3 mg.kg(‐1)
Study: 1805295
Drug: Ethanol 1
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 1 g/kg body weight
Study: 23934621
Drug: Ethanol 0.5
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.5 g/kg body weight
Study: 27084954
Drug: Methotrexate 40
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 40 mg/m2/week
Study: 25243574
Drug: T4 treatment
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 treatment (N = 64)
Study: 25243574
Drug: T4 treatment
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 treatment (N = 64) with TSH ≥ 5 mIU/L
Study: 25243574
Drug: T4 treatment
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 treatment (N = 64) with TSH < 5 mIU/L
Study: 25243574
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (N = 59)
Study: 7485222
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ibuprofen three times daily for 1 month
Study: 7485222
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg piroxicam daily for 1 month
Study: 7485222
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sulindac twice daily for 1 month
Study: 4023472
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A or B
Study: 4023472
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C or D
Study: 28745470
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (3 g of taurine with 400 mL low fat chocolate milk)
Study: 28745470
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) with 400 mL low fat chocolate milk
Study: 26425113
Drug: Usual monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Usual monthly group meetings (Control).
Study: 21617573
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (2 doses, 6 to 9 months apart)
Study: 21617573
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine coadministered with MMR and varicella vaccines (2 doses of hepatitis A vaccine, 6 to 9 months apart)
Study: 21617573
Drug: MMR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR and varicella vaccines followed by 2 doses of hepatitis A vaccine (6 weeks later, 6 to 9 months apart)
Study: 16865082
Drug: Levobupivacaine 0.5%
Normalized name: levobupivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.5% (group L)
Study: 12699469
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 micro g daily)
Study: 9603637
Drug: Norfloxacin 800
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin 800 mg once-daily (Group A)
Study: 9603637
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg twice-daily (Group B)
Study: 3350994
Drug: Prednisone (PN)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (PN) 10-mg oral tablet
Study: 3350994
Drug: Prednisolone (PL)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (PL) 10-mg oral tablet
Study: 3350994
Drug: Intravenous Prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Prednisone (IV PN) 10-mg
Study: 3350994
Drug: Intravenous Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Prednisolone (IV PL) 10-mg
Study: 28548898
Drug: Rapid albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid albuterol pathway with a breath-enhanced nebulizer (up to 4 treatments)
Study: 28548898
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment arm (up to 2 continuous albuterol nebulizations)
Study: 22945731
Drug: Irrigation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigation with a hydroalcoholic solution of propolis extract twice a week for 2 weeks (group A)
Study: 22945731
Drug: Irrigation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigation with a placebo twice a week for 2 weeks (group B)
Study: 22945731
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (group C)
Study: 20490472
Drug: Blonanserin 2
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin 2 mg oral dose, administered under different conditions: fasting, 30 min before meal, 30 min after meal, 2 h after meal, 4 h after meal.
Study: 26334929
Drug: STRIDE lifestyle
Normalized name: Stridex
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STRIDE lifestyle intervention (weekly group meetings for 6 months, then monthly for 6 months)
Study: 21198745
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (patients on dopamine agonist therapy)
Study: 19101780
Drug: Olmesartan (RAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (RAS inhibitor)
Study: 19101780
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs without RAS inhibitors
Study: 3370020
Drug: 9-week program
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-week program of submaximal aerobic exercise three times weekly
Study: 25084971
Drug: Antibiotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic group (first-line antibiotics for 3 days)
Study: 25084971
Drug: No Antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Antibiotic group
Study: 22345687
Drug: Pitavastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (2 mg initially, increasing to 4 mg after 8 weeks if necessary)
Study: 22345687
Drug: Pitavastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (2 and 4 mg)
Study: 22157744
Drug: Ultrasound-guided interfascial
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided interfascial injection of 5 mL of lidocaine 2%
Study: 22157744
Drug: Nerve stimulation-assisted
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve stimulation-assisted technique with 5 mL of lidocaine 2%
Study: 20501476
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) administered pre-sheath (before catheterization laboratory arrival)
Study: 20501476
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) administered in-lab (after catheterization laboratory arrival)
Study: 17711924
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen (17beta-estradiol) at doses of 0.5, 1, and 2 mg for 2 weeks each
Study: 17711924
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (TD) at doses of 0.025, 0.0375, and 0.05 mg for 2 weeks each
Study: 16334438
Drug: L-NMMA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (4 mg kg-1 h-1)
Study: 2478015
Drug: ATIII/heparin regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATIII/heparin regimen (1,500 units preoperatively and 1,000 units daily for five days)
Study: 2478015
Drug: ATIII (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATIII (same dose as hip replacement)
Study: 2478015
Drug: ATIII (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATIII (twice the dose used for hip replacement)
Study: 2478015
Drug: ATIII/heparin, warfarin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATIII/heparin, warfarin, or dextran
Study: 1266558
Drug: DHB 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHB 0.2 mg/kg
Study: 1266558
Drug: Pentobarbital 2
Normalized name: pentobarbital 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital 2 mg/kg
Study: 1266558
Drug: Halothane with
Normalized name: Halothane
DrugBank: Halothane (DB01159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halothane with pentobarbital 2 mg/kg
Study: 31035902
Drug: Control (nonstatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (nonstatin treatment)
Study: 26711466
Drug: Mouthwash and
Normalized name: SODIUM FLUORIDE 2.4 mg in 1 g DENTAL GEL, DENTIFRICE [AIM TARTAR CONTROL Plus Mouthwash and Whitening]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash and a moisturizing gel (M + m)
Study: 26711466
Drug: Water and
Normalized name: ALCOHOL 71 mL in 100 mL TOPICAL GEL [Anti Bacterial Hand Gel Rose Water and Ivy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water and a moisturizing gel (W + m)
Study: 27099884
Drug: Ongoing GDMT
Normalized name: Ongo-Fin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing GDMT plus carotid baroreflex activation therapy (BAT) for 6 months
Study: 23484763
Drug: Bepotastine besilate
Normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bepotastine besilate ophthalmic solution (BBOS) 1.5%
Study: 18271228
Drug: Estazolam (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam (oral administration)
Study: 15780846
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Delta‐9‐THC
Study: 16988594
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg CBD
Study: 16988594
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg CBD
Study: 11035338
Drug: Standard corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard corticosteroid dosage regimen for promotion of fetal lung maturation
Study: 11035338
Drug: High-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroid regimen of >24 mg/d (10 mg dexamethasone IV every 6 hours for 2 doses followed by 6 mg IV every 6 hours for 2 to 4 doses)
Study: 9447770
Drug: Colgate 0-6
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate 0-6 gel (400 ppm F)
Study: 30403954
Drug: Ceftriaxone 500
Normalized name: ceftriaxone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 500 mg
Study: 29146890
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea ointment 3%
Study: 27107670
Drug: Benzodiazepine dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine dosage reduction
Study: 22908105
Drug: Moving to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moving to Opportunity (MTO) treatment (voucher for lower-poverty neighborhoods)
Study: 16293412
Drug: Dydrogesterone 40
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dydrogesterone 40 mg stat dose followed by 10 mg twice a day for one week
Study: 7502999
Drug: Plasma selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma selenium levels in cases with MI (mean 114.4 ± 15.1 ng/g)
Study: 7502999
Drug: Plasma selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma selenium levels in controls (mean 113.2 ± 15.7 ng/g)
Study: 2102136
Drug: Ketanserin 20
Normalized name: ketanserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20 mg b.i.d.
Study: 2935497
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg b.i.d.
Study: 2102136
Drug: Ketanserin 20
Normalized name: ketanserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20 mg b.i.d. and 40 mg b.i.d.
Study: 86158
Drug: Topical 10%
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10% adenine arabinoside 5'-monophosphate
Study: 22331175
Drug: Melatonin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (4 mg)
Study: 26153671
Drug: Infant-daily nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infant-daily nevirapine
Study: 19695526
Drug: Microcurrent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcurrent therapy (30 minutes) followed by stretching exercises (2 minutes); 3 treatments per week for 2 weeks.
Study: 19695526
Drug: Stretching exercises
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching exercises after ultrasound therapy (30 minutes); 3 treatments per week for 2 weeks.
Study: 12764910
Drug: Shengmai Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengmai Injection (SMI) plus conventional treatment of western medicine
Study: 1917174
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment (two 10 mg/24 hour patches twice daily, at 8 a.m. and 8 p.m.)
Study: 1917174
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment (two 10 mg/24 hour patches at 8 a.m. and two placebo patches at 8 p.m.)
Study: 1917174
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two placebo patches twice daily, at 8 a.m. and 8 p.m.)
Study: 19664956
Drug: Standard topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard topical 4% lidocaine cream and injection of [(99m)Tc]Tc‐sulfur colloid (n=35)
Study: 19664956
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo cream and injection of Tc‐sulfur colloid containing sodium bicarbonate (n=35)
Study: 19664956
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo cream and injection of Tc‐sulfur colloid containing 1% lidocaine (n=35)
Study: 19664956
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo cream and injection of Tc‐sulfur colloid containing sodium bicarbonate and 1% lidocaine (n=35)
Study: 16398423
Drug: Xiaoshui Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoshui Decoction (XSD) combined with chemotherapy (DDP via abdominal infusion)
Study: 16398423
Drug: DDP infusion
Normalized name: DDP-200
DrugBank: DDP-200 (DB05919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDP infusion alone (control group)
Study: 12526189
Drug: Selective estrogen
Normalized name: Selective estrogen receptor modulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective estrogen receptor modulators (SERMs)
Study: 9690723
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg t.d.s.)
Study: 9690723
Drug: Tripotassium dicitrato
Normalized name: Tripotassium dicitratobismuthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripotassium dicitrato bismuthate (TDB) (120 mg q.d.s.)
Study: 8620674
Drug: Zileuton 800mg
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zileuton 800mg twice daily
Study: 2703967
Drug: Methocarbamol 2.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methocarbamol 2.25, 4.5, and 9 g
Study: 2703967
Drug: Lorazepam 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1, 2, and 4 mg
Study: 22982605
Drug: d‐amphetamine (20mg-oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐amphetamine (20mg-oral)
Study: 22982605
Drug: haloperidol (2mg-oral)
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: haloperidol (2mg-oral)
Study: 16935686
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate 100 mug twice daily
Study: 16935686
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate 100 mug twice daily (open-label added if symptoms not controlled)
Study: 12813384
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g bolus before incision, 200 mg/hour infusion during surgery)
Study: 8707761
Drug: Adjunctive cytokine
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive cytokine and progenitor cell support of hematologic recovery after myelosuppressive therapy
Study: 1511228
Drug: Clonidine or
Normalized name: clonidine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine or guanfacine treatment
Study: 28994675
Drug: Dexmedetomidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.4 μg/kg/h continuous infusion
Study: 28994675
Drug: Dopamine 3
Normalized name: DOPamine 3.2 mg/mL-D5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine 3 μg/kg/min continuous infusion
Study: 22802974
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg rSh28GST with aluminium hydroxide (Alum) as adjuvant (n=8)
Study: 22802974
Drug: 300 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 µg rSh28GST (n=8)
Study: 19006541
Drug: Ranitidine effervescent
Normalized name: ranitidine Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine effervescent tablets 75 mg (on-demand)
Study: 19006541
Drug: Lansoprazole capsules
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole capsules 15 mg (on-demand)
Study: 17768579
Drug: Amiodarone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (600 mg/day to 900 mg/day intravenously on the first postoperative day, followed by 400 mg/day orally until hospital discharge or until completing seven days)
Study: 11350207
Drug: D-tagatose (3x15
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-tagatose (3x15 g daily)
Study: 11350207
Drug: Placebo (sucrose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sucrose, 3x15 g daily)
Study: 25400667
Drug: Royal Jelly
Normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Royal Jelly (RJ) applied three times per day during treatment
Study: 23299850
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of PRP (Group A)
Study: 23299850
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of PRP (Group B)
Study: 20225605
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy considerations
Study: 10867980
Drug: Clonidine hydrochloride
Normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine hydrochloride 0.2 mg
Study: 10867980
Drug: Yohimbine hydrochloride
Normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine hydrochloride 22 mg
Study: 10867980
Drug: Clonidine hydrochloride
Normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine hydrochloride 0.2 mg + Yohimbine hydrochloride 22 mg
Study: 1590547
Drug: 0.6 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g/kg dose of ethanol
Study: 1590547
Drug: Placebo dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose
Study: 28295934
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (IDeg) 0.4 U/kg once daily
Study: 22594461
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (IGlar) 0.4 U/kg once daily